HomeCompareSTGPF vs ABBV

STGPF vs ABBV: Dividend Comparison 2026

STGPF yields 6.03% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 STGPF wins by $18107.28M in total portfolio value
10 years
STGPF
STGPF
● Live price
6.03%
Share price
$2.00
Annual div
$0.12
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18107.38M
Annual income
$17,547,964,434.92
Full STGPF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — STGPF vs ABBV

📍 STGPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSTGPFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, STGPF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
STGPF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

STGPF
Annual income on $10K today (after 15% tax)
$512.21/yr
After 10yr DRIP, annual income (after tax)
$14,915,769,769.68/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, STGPF beats the other by $14,915,748,713.68/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of STGPF + ABBV for your $10,000?

STGPF: 50%ABBV: 50%
100% ABBV50/50100% STGPF
Portfolio after 10yr
$9053.74M
Annual income
$8,773,994,603.34/yr
Blended yield
96.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

STGPF
No analyst data
Altman Z
1.2
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

STGPF buys
0
ABBV buys
0
No recent congressional trades found for STGPF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSTGPFABBV
Forward yield6.03%3.06%
Annual dividend / share$0.12$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$18107.38M$102.3K
Annual income after 10y$17,547,964,434.92$24,771.77
Total dividends collected$18068.63M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: STGPF vs ABBV ($10,000, DRIP)

YearSTGPF PortfolioSTGPF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,905$1,205.20$11,550$430.00+$355.00STGPF
2$15,420$2,681.90$13,472$627.96+$1.9KSTGPF
3$22,993$6,493.05$15,906$926.08+$7.1KSTGPF
4$42,699$18,096.41$19,071$1,382.55+$23.6KSTGPF
5$108,502$62,814.55$23,302$2,095.81+$85.2KSTGPF
6$414,450$298,352.23$29,150$3,237.93+$385.3KSTGPF
7$2,573,602$2,130,140.68$37,536$5,121.41+$2.54MSTGPF
8$27,478,055$24,724,300.57$50,079$8,338.38+$27.43MSTGPF
9$522,819,360$493,417,841.10$69,753$14,065.80+$522.75MSTGPF
10$18,107,381,150$17,547,964,434.92$102,337$24,771.77+$18107.28MSTGPF

STGPF vs ABBV: Complete Analysis 2026

STGPFStock

Scentre Group (ASX Code: SCG) is the owner and operator of Westfield in Australia and New Zealand with interests in 42 Westfield Living Centres, encompassing approximately 12,000 outlets.

Full STGPF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this STGPF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

STGPF vs SCHDSTGPF vs JEPISTGPF vs OSTGPF vs KOSTGPF vs MAINSTGPF vs JNJSTGPF vs MRKSTGPF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.